Coxibs cardiovascular safety

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications. The main mechanism of action of these drugs is the inhibition of cyclooxygenase (COX). This mechanism is associated not only with the therapeutic effects of NSAIDs, but also with adverse drug reactions, in particular, an increase in cardiovascular risk. The purpose of this review was to summarize the currently available data on the cardiovascular safety of highly selective COX-2 inhibitors called coxibs. It has been shown that cardiovascular side effects are class-specific effects of NSAIDs, independent on COX-2 selectivity. In general, coxibs have cardiovascular safety comparable to non-selective NSAIDs with a better gastrointestinal safety profile. However, there are certain differences between effects of certain drugs on blood pressure, heart rate, heart failure, the frequency of fatal and non-fatal cardiovascular events.

Full Text

Restricted Access

About the authors

Laura Z. Bolieva

North Ossetian State Medical Academy of the Ministry of Healthcare of Russia

Author for correspondence.
Email: bolievalz@mail.ru
ORCID iD: 0000-0002-6977-7534

MD, professor, head of the Department of pharmacology with clinical pharmacology

Russian Federation, Vladikavkaz

Tatyana V. Adasheva

A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: adashtv@mail.ru
ORCID iD: 0000-0002-3763-8994

MD, professor of the Department of therapy and preventive medicine

Russian Federation, Moscow

Madina D. Daurova

North Ossetian State Medical Academy of the Ministry of Healthcare of Russia

Email: daurovamadina@yandex.ru

PhD in Medical Sciences, associate professor of the Department of pharmacology with clinical pharmacology

Russian Federation, Vladikavkaz

References

  1. Pakhomova I.G. NSAID-associated lesions of the gastrointestinal tract and their complications: ways of preventing. Consilium Medicum. 2017; 19(9): 109–113 (In Russ.). https://dx.doi.org/10.26442/2075-1753_19.9.109-113. EDN: ZTWMOR.
  2. Hawkey C.J. COX-2 chronology. Gut. 2005; 54(11): 1509–14. https://dx.doi.org/10.1136/gut.2005.065003.
  3. Van Hecken A., Schwartz J., Depre M. et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000; 40(10): 1109–20. https://dx.doi.org/10.1177/009127000004001005.
  4. Capone M., Tacconelli S., Sciulli M., Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol. Pharmacol. 2003; 16(2 Suppl.): 49–58.
  5. Singh G., Fort J., Goldstein J. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006; 119(3): 255–66. https://dx.doi.org/10.1016/j.amjmed.2005.09.054.
  6. Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2006; 368(9549): 1771–81. https://dx.doi.org/10.1016/S0140-6736(06)69666-9.
  7. Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003; 98(8): 1725–33. https://dx.doi.org/10.1111/j.1572-0241.2003.07598.x.
  8. Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2007; 369(9560): 465–73. https://dx.doi.org/10.1016/S0140-6736(07)60234-7.
  9. Silverstein F., Faich G., Goldstein J. et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000; 284(10): 1247–55. https://dx.doi.org/10.1001/jama.284.10.1247.
  10. Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet. 2010; 376(9736): 173–79. https://dx.doi.org/10.1016/S0140-6736(10)60673-3.
  11. Moore R., Derry S., Makinson G., McQuay H. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systemic review and meta-analysis on information from company clinical reports. Arthritis Res Ther. 2005; 7(3): R644–65. https://dx.doi.org/10.1186/ar1704.
  12. Bresalier R., Sandler R., Quan H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352(11): 1092–102. https://dx.doi.org/10.1056/NEJMoa050493.
  13. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343(21): 1520–28. https://dx.doi.org/10.1056/NEJM200011233432103.
  14. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet. 2004; 364(9450): 1995–96. https://dx.doi.org/10.1016/S0140-6736(04)17523-5.
  15. Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329(7478): 1308. https://dx.doi.org/10.1136/bmj.329.7478.1308.
  16. Ott E., Nussmeier N.A., Duke P.C. et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003; 125(6): 1481–92. https://dx.doi.org/10.1016/s0022-5223(03)00125-9.
  17. Nussmeier N., Whelton A., Brown M. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352(11): 1081–91. https://dx.doi.org/10.1056/NEJMoa050330.
  18. Melnikova I. Future of COX 2 inhibitors. Nat Rev Drug Discov. 2005; 4(6): 453–54. https://dx.doi.org/10.1038/nrd1755.
  19. Patrignani P., Tacconelli S., Bruno A. et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin. Pharmacol. 2011; 4(5): 605–21. https://dx.doi.org/10.1586/ecp.11.36.
  20. Hocherl K., Endemann D., Kammerl M.C. et al. Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol. 2002; 136(8): 1117–26. https://dx.doi.org/10.1038/sj.bjp.0704821.
  21. Qi Z., Hao C.M., Langenbach R.I. et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002; 110(1): 61–69. https://dx.doi.org/10.1172/JCI14752.
  22. Bulut D., Liaghat S., Hanefeld C. et al. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens. 2003; 21(9): 1663–67. https://dx.doi.org/10.1097/00004872-200309000- 00015
  23. Fosbol E.L., Folke F., Jacobsen S. et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010; 3(40): 395–405. https://dx.doi.org/10.1161/CIRCOUTCOMES.109. 861104.
  24. Sudano I., Flammer A.J., Roas S. et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012; 14(4): 304–9. https://dx.doi.org/10.1007/s11906-012-0274-7.
  25. Liew J.W., Ward M.M., Reveille J.D. et al. Nonsteroidal anti-inflammatory drug use is associated with incident hypertension in ankylosing spondylitis. Аrthritis Care Res. 2020; 72(11): 1645–52. https://dx.doi.org/10.1002/acr.24070.
  26. Mitchell J.A., Kirkby N.S. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2019; 176(8): 1038–50. https://dx.doi.org/10.1111/bph.14167.
  27. Cheng H.F., Harris R.C. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004; 43(3): 525–30. https://dx.doi.org/10.1161/01. HYP.0000116221.27079.
  28. Bertagnolli M.M., Eagle J. Craig, Zauber A.G. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355(9): 873–84. https://dx.doi.org/10.1056/NEJMoa061355.
  29. Schwartz J.I., Tach C., Lasseter K.C. et al. Efects of etoricoxib and comparator nonsteroidal anti-infammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. Clinical Pharmacol. 2007; 47(12): 1521–31. https://dx.doi.org/10.1177/0091270007307878.
  30. Sowers J.R., White W.B., Pitt B.et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-infammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165(2): 161–68. https://dx.doi.org/10.1001/archinte.165.2.161.
  31. Ruschitzka F., Borer J.S., Krum H. et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017; 38(44): 3282–92. https://dx.doi.org/10.1093/eurheartj/ehx508.
  32. Zhang J., Ding E.L., Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials. JAMA. 2006; 296(13): 1619–32. https://dx.doi.org/10.1001/jama.296.13.jrv60015.
  33. Chan C.C., Reid C.M., Aw T.-J. et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009; 27(12): 233 –41. https://dx.doi.org/10.1097/HJH.0b013e3283310dc9.
  34. Krum H., Swergold G., Curtis S.P. et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: Results from the MEDAL study. J Hypertens. 2009; 27(4): 886–93. https://dx.doi.org/10.1097/HJH.0b013e328325d831.
  35. Merck Sharp & Dohme Ltd. Arcoxia 30, 60, 90, 120 mg flmcoated tablets [prescribing information]. 2016. URLL https://www.medicines.org.uk/emc/product/3302/smpc (date of access – 01.05.2023).
  36. State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for the medical use of the drug Arcoxia. RC: ЛП-№(000508)-(РГ-RU) dated 11/10/2022. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8dc6aa35-d3cb-4481-8319-133fb69708dd (date of access – 01.05.2023) (In Russ.).
  37. Accord-UK Ltd. Diclofenac potassium 50 mg tablets prescribing information. 2017. URL: https://www.medicines.org.uk/emc/ product/4515/smpc (date of access – 01.05.2023).
  38. State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for the medical use of the drug Voltaren. RC: П N015266/01 dated 03/14/2018. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0d8e9f05-2494-405a-b1c7-9cb02c510324 (date of access – 01.05.2023) (In Russ.).
  39. Pfizer Ltd. Celebrex 100 mg capsule [prescribing information]. 2017. URL: https://www.medicines.org.uk/emc/product/5533/smpc (date of access – 01.05.2023)
  40. State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for the medical use of the drug Celebrex. RC: ЛП-002118 dated 10/13/2022. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f6829510-dc1a-4ff3-85d7-b986ae5bdb2e (date of access – 01.05.2023) (In Russ.).
  41. Chenevard R., Hurlimann D., Bechir M. et al. Selective COX2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003; 107(3): 405–9. https://dx.doi.org/10.1161/01.CIR.0000051361.69808.3A.
  42. Walter M.F., Jacob R.F., Day C.A. et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modifcation: Comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004; 177(2): 235–43. https://dx.doi.org/10.1016/j.atherosclerosis.2004.10.001.
  43. Widlansky M.E., Price D.T., Gokce N. et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003; 42(3): 310–15. https://dx.doi.org/10.1161/01.HYP.0000084603.93510.28.
  44. Arfe A., Scotti L., Varas-Lorenzo C. et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016; 354: i4857. https://dx.doi.org/10.1136/bmj.i4857.
  45. Hudson M., Richard H., Pilote L. Different in outcome of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: Population based study. BMJ. 2005; 330(7504): 1370. https://dx.doi.org/10.1136/bmj.330.7504.1370
  46. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(5): 677–80. https://dx.doi.org/10.1093/rheumatology/keh610.
  47. Mamdani M., Juurlink D.N., Lee D.S. et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in eldery patients: A population-based cohort study. Lancet. 2004; 363(9423): 1751–56. https://dx.doi.org/10.1016/S0140-6736(04)16299-5.
  48. Ungprasert P., Srivali N., Thongprayoon C. Nonsteroidal antiinflammatory drugs and risk of incident heart failure: A systematic review and meta-analysis of observational studies. Clin Cardiol. 2016; 39(2): 111–18. https://dx.doi.org/10.1002/clc.22502.
  49. Scott P.A., Kingsley G.H., Scott D.L. Non-steroidal anti-inflammatory drugs and cardiac failure: Meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008; 10(11): 1102–7. https://dx.doi.org/10.1016/j.ejheart.2008.07.013.
  50. Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Sci. 2013; 16(5): 821–47. https://dx.doi.org/10.18433/J3VW2F.
  51. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenes an opportunities. J Clin Invest. 2006; 116(1): 4–15. https://dx.doi.org/10.1172/JCI27291.
  52. Schaeverbeke T., Heloire F., Deray G. [How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk? Presse Med. 2006; 35 Suppl 1: 41–46 (In French)]. https://dx.doi.org/10.1016/S0755- 4982(06)74939-9.
  53. Back M., Yin L., Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 2012; 33(15): 1928–33. https://dx.doi.org/10.1093/eurheartj/ehr421.
  54. Schmidt M., Christiansen C.F., Mehnert F. et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: Population based case-control study. BMJ. 2011; 343: d3450. https://dx.doi.org/10.1136/bmj.d3450.
  55. Cheng Y., Austin S.C., Rocca B. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296(5567): 539–41. https://dx.doi.org/10.1126/science.1068711.
  56. Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001; 345(25): 1809–17. https://dx.doi.org/10.1056/NEJMoa003199.
  57. Capone M.L., Sciulli M.G., Tacconelli S. et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005; 45(8): 1295–301. https://dx.doi.org/10.1016/j.jacc. 2005.01.045.
  58. Wilner K.D., Rushing M., Walden C. et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthe volunteers. J Clin Pharmacol. 2002; 42(9): 1027–30. https://dx.doi.org/10.1177/ 0091270002042009010.
  59. Laine L., White W.B., Rostom A., Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum. 2008; 38(3): 165–87. https://dx.doi.org/10.1016/j.semarthrit.2007. 10.004.
  60. Vonkeman H.E., Brouwers J.R., van de Laar M.A. Understanding the NSAID related risk of vascular events. BMJ. 2006; 332(7546): 895–98. https://dx.doi.org/10.1136/bmj.332.7546.895.
  61. Fosbol E.L., Kober L., Torp-Pedersen C., Gislason G.H. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf. 2010; 9(6): 893–903. https://dx.doi.org/10.1517/14740338.2010.501331
  62. Gislason G.H., Jacobsen S., Rasmussen J.N. et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006; 113(25): 2906–13. https://dx.doi.org/10.1161/CIRCULATIONAHA.106.616219.
  63. Schjerning Olsen A.M., Gislason G.H., McGettigan P. et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015; 313(8): 805–14. https://dx.doi.org/10.1001/jama.2015.0809.
  64. Masclee G.M.C., Straatman H., Arfe A. et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018; 13(11): 0204746. https://dx.doi.org/10.1371/journal.pone.0204746.
  65. Bhala N., Emberson J., Merhi A. Vascular and upper gastrointestinal efects of non-steroidal anti-infammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769–79. https://dx.doi.org/10.1016/S0140-6736(13)60900-9.
  66. Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal anti-infammatory drugs: Network metaanalysis. BMJ. 2011; 342: c7086. https://dx.doi.org/10.1136/bmj.c7086.
  67. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-infammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 2011; 8(9): e1001098. https://dx.doi.org/10.1371/journal.pmed.1001098.
  68. White W.B., Faich G., Whelton A. et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specifc inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89(4): 425–30. https://dx.doi.org/10.1016/s0002-9149(01)02265-2.
  69. Nissen S.E., Yeomans N.D., Solomon D.H. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016; 375(26): 2519–29. https://dx.doi.org/10.1056/NEJMoa1611593.
  70. Strand V. Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007; 370(9605): 2138–51. https://dx.doi.org/10.1016/S0140-6736(07)61909-6.
  71. Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018; 56(Suppl. 1): 1–29 (In Russ.). https://dx.doi.org/10.14412/1995-4484-2018-1-29.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Synthesis of prostaglandins and the principle of action of non-steroidal anti-inflammatory drugs

Download (255KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies